Clinical Trial Update: Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating treatment for graft-versus-host disease in patients with recurrent or refractory lymphoma or Hodgkin's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Graft Versus Host Disease, Lymphoma | Phase 3 | Status: COMPLETED